You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Corrigan RR, Labrador L, Grizzanti J, et al. (2023) Neuroprotective Mechanisms of Amylin Receptor Activation, Not Antagonism, in the APP/PS1 Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 91: 1495-1514
Correia SC, Alves MG, Oliveira PF, et al. (2022) Hypoxic preconditioning averts sporadic Alzheimer's disease-like phenotype in rats: a focus on mitochondria. Antioxidants & Redox Signaling
Corrigan RR, Piontkivska H, Casadesus G. (2021) Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment. Current Neuropharmacology
Mey M, Bhatta S, Casadesus G. (2021) Luteinizing hormone and the aging brain. Vitamins and Hormones. 115: 89-104
Cunnane SC, Trushina E, Morland C, et al. (2020) Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews. Drug Discovery
Ettcheto M, Sánchez-López E, Gómez-Mínguez Y, et al. (2020) Correction to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. Molecular Neurobiology
Servizi S, Corrigan RR, Casadesus G. (2020) The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer’s Disease Current Pharmaceutical Design
Busquets O, Ettcheto M, Eritja À, et al. (2019) c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine (Berlin, Germany)
Folch J, Olloquequi J, Ettcheto M, et al. (2019) The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. Frontiers in Aging Neuroscience. 11: 236
Grizzanti J, Corrigan R, Servizi S, et al. (2019) Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology? Journal of Neurology & Neuromedicine. 4: 12-16